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STRATEGIES	TO	CONTINUE	STATIN	USE		 	 14		included	were	considered	statin	intolerant	by	failing	therapy	of	two	or	more	agents	along	with	low	serum	vitamin	D	levels	less	than	32	ng/mL.		Patients	with	previously	reported	rhabdomyolysis,	those	taking	corticosteroids,	or	those	with	any	comorbidity	that	could	lead	to	muscle	or	bone	pain	were	excluded.		The	patients	were	given	either	50,000	or	100,000	units	per	week	of	vitamin	D2	to	correct	the	deficiency.		Vitamin	D	doses	were	adjusted	to	maintain	a	normal	range	of	50	to	80	ng/mL.		Patients	were	then	given	rosuvastatin	10	to	20	mg	daily	three	weeks	after	the	vitamin	D	initiation.		Statin	dosing	was	also	adjusted	in	an	attempt	to	reduce	LDL	to	meet	ATP	III	goals.		Patients	completed	follow-up	at	six	months,	12	months,	and	24	months	(Khayznikov	et	al.,	2015).		Of	the	146	patients,	88	to	95%	were	able	to	tolerate	statin	therapy	without	recurrent	“myalgia,	myositis,	myopathy,	and/or	myonecrosis”	with	median	vitamin	D	supplementation	of	50,000	units	per	week	(Khayznikov	et	al.,	2015,	p.	90).		The	authors	concluded	that	statin	intolerance	due	to	adverse	muscular	effects	is	associated	with	vitamin	D	deficiency	and	can	be	resolved	by	supplementation.		Additionally,	vitamin	D	has	proven	to	be	well	tolerated	and	its	safety	is	not	a	concern	(Khayznikov	et	al.,	2015).		 In	another	prospective	cohort	designed	study,	the	goal	of	the	authors	was	to	determine	if	low	serum	vitamin	D	levels	correlate	to	myalgia	in	patients	on	statin	therapy,	and	if	the	symptoms	can	be	reversed	by	adding	supplementation.		Of	the	621	patients	who	had	vitamin	D	levels	drawn,	128	complained	of	myalgia.		The	vitamin	D	levels	were	low	in	64%,	or	82,	of	the	patients	with	myalgia	symptoms	compared	to	43%	of	the	patients	without	symptoms.		Of	the	82	patients	with	myalgia,	38	had	vitamin	D	levels	below	32	ng/mL	and	were	instructed	to	take	
STRATEGIES	TO	CONTINUE	STATIN	USE		 	 15		50,000	units	per	week	of	vitamin	D	for	12	weeks.		They	were	allowed	to	continue	their	current	statin	medication,	which	included	rosuvastatin,	atorvastatin,	or	pravastatin	(Ahmed	et	al.,	2009).		At	the	end	of	the	study	period,	Ahmed	et	al.	(2009)	determined,	“vitamin	D	supplementation	that	normalized	serum	vitamin	D	levels	was	concurrently	associated	with	resolution	of	myalgias	in	35	of	38	(92%)	statin-treated	patients	with	myalgia	and	low	pretreatment	serum	vitamin	D	levels”	(p.	15).		The	authors	did	recognize	some	study	limitations,	which	included	subjective	reporting	of	myalgia	symptoms	by	patients,	lack	of	blinding,	and	not	having	a	control	group	(Ahmed	et	al.,	2009).		 Glueck,	Abuchaibe,	and	Wang	(2011)	also	presented	a	prospective	study	where	68	patients	diagnosed	with	hypercholesterolemia,	unable	to	tolerate	at	least	one	statin	due	to	myositis/myalgia,	and	with	low	serum	25	(OH)	vitamin	D	levels	less	than	32	ng/mL	were	evaluated	to	identify	if	vitamin	D	deficiency	correction	would	result	in	tolerance	of	statin	therapy.		Patients	were	given	50,000	units	of	vitamin	D2	twice	weekly	for	three	weeks	and	then	they	continued	once	weekly	dosing.		Statin	therapy	was	restarted	after	the	initial	three	weeks	of	vitamin	D	supplementation.		Patients	were	assessed	at	three	months,	and	91%	of	the	patients	were	able	to	tolerate	statin	therapy	with	vitamin	D	supplementation	(Glueck,	Abuchaibe,	&	Wang,	2011).		 A	retrospective	chart	review	of	450	patients	taking	simvastatin	80	mg	was	conducted	and	found	that	11.1%	of	patients	reported	myalgia	along	with	one	patient,	or	0.22%,	who	developed	rhabdomyolysis.		The	study	aimed	to	determine	whether	or	not	low	vitamin	D	levels	contribute	to	the	risk	of	developing	myalgia	
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